Disease Overview：Global heart failure（GHF）
Heart failure—specifically, biventricular or global heart failure—is a progressive clinical syndrome characterized by structural or functional impairment of ventricular filling or ejection of blood, resulting in inadequate cardiac output to meet systemic metabolic demands. It commonly arises from underlying conditions such as ischemic heart disease, dilated cardiomyopathy, valvular dysfunction, or long-standing hypertension. Symptoms include dyspnea, orthopnea, fatigue, peripheral edema, and reduced exercise tolerance. Diagnosis relies on comprehensive evaluation: echocardiography (including LVEF and diastolic function assessment), BNP/NT-proBNP testing, cardiac MRI, and sometimes invasive hemodynamic monitoring. Management follows guideline-directed medical therapy (GDMT)—comprising ACE inhibitors/ARBs/ARNIs, beta-blockers, MRAs, and SGLT2 inhibitors—alongside device-based interventions (CRT, ICD) or advanced therapies like mechanical circulatory support or heart transplantation in refractory cases.
China offers distinct advantages for global patients seeking high-quality heart failure care. Leading cardiovascular centers—such as Fu Wai Hospital (National Center for Cardiovascular Diseases) and Shanghai Ruijin Hospital—combine deep expertise in complex heart failure management with cutting-edge technology, including 3T cardiac MRI, real-time 3D echocardiography, and minimally invasive valve repair platforms. Clinical outcomes align with international benchmarks: 5-year survival rates for optimized chronic heart failure exceed 70%, and transplant wait times are significantly shorter than in many Western countries. Crucially, treatment costs—including diagnostics, GDMT, CRT implantation, or even heart transplantation—are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based standards.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: coordinating appointments with top-tier cardiologists and heart failure specialists, verifying hospital accreditation and procedural volumes, providing transparent, all-inclusive pricing (covering consultations, diagnostics, procedures, medications, and follow-up), and offering end-to-end support—from visa assistance and medical translation to accommodation and post-discharge coordination.
Global heart failure: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Biventricular Heart Failure (Cardiology Department)
Non-Surgical / Conservative Management
*Target criteria:* NYHA Class II–III, stable hemodynamics, preserved renal/hepatic function, no acute decompensation.
- •Core Medication Regimen (Monthly):
- Beta-blocker (e.g., carvedilol): $4–$12 - MRA (e.g., spironolactone): $2–$5 - SGLT2 inhibitor (e.g., dapagliflozin): $32–$78 - Diuretic (furosemide IV/oral): $1–$4
- •Essential Monitoring (Per Visit):
- Renal panel (Cr, eGFR, Na⁺, K⁺): $12 - ECG + echocardiogram (TTE): $42 - 24-h Holter monitoring: $35
- •Tiered Follow-up Fees (Outpatient):
- Advanced HF nurse-led telemonitoring (monthly): $22
Surgical / Procedural Interventions
*Eligibility:* LVEF ≤35%, QRS ≥150 ms (LBBB), optimal GDMT ≥3 months, no contraindications to device implantation or surgery.
- •CRT-D Implantation:
- Device + implantation (domestic vs. imported): $4,800–$9,600
- •ICD Implantation (primary prevention):
- Device + implantation: $3,200–$6,900
- •Heart Transplant Evaluation & Listing:
- Annual listing maintenance (including repeat testing): $1,420
- •LVAD Implantation (Bridge-to-Transplant):
- Device + surgery + ICU stay (7–14 days): $42,000–$58,000
Special/Complex Condition Options
- •Acute Decompensated HF (ADHF) Admission (7-day stay, Grade 3A ICU):
- •Amyloidosis-Specific Therapy (ATTR-CM):
- Cardiac MRI + bone scintigraphy (pre-treatment confirmation): $520
- •Refractory HF with Severe TR:
Quick Selection Guide
- •Age <65, LVEF ≤25%, no comorbidities: CRT-D + GDMT ($5,000–$10,000 initial) — highest survival benefit.
- •Age ≥75, NYHA IV, limited mobility, budget <$5,000: Optimized oral GDMT + home telemonitoring ($120–$200/month) — avoids procedural risk.
- •ADHF with multiorgan failure: Urgent ICU admission ($8,400+) — mandatory before considering advanced devices.
- •Confirmed ATTR-CM: Tafamidis + specialist monitoring ($1,800/month total) — disease-modifying and cost-effective long-term.
- •End-stage, transplant-ineligible, severe TR: TriClip ($22,500) — improves functional status when surgery is prohibitive.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Global heart failure Medical Vacation Packages
Curated transparent all-inclusive packages combining Global heart failure treatment with China top medical destinations:
